1
|
Hagihara M, Yamashita M, Ariyoshi T, Eguchi S, Minemura A, Miura D, Higashi S, Oka K, Nonogaki T, Mori T, Iwasaki K, Hirai J, Shibata Y, Umemura T, Kato H, Asai N, Yamagishi Y, Ota A, Takahashi M, Mikamo H. Clostridium butyricum-induced ω-3 fatty acid 18-HEPE elicits anti-influenza virus pneumonia effects through interferon-λ upregulation. Cell Rep 2022; 41:111755. [PMID: 36516771 DOI: 10.1016/j.celrep.2022.111755] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 07/11/2022] [Accepted: 11/09/2022] [Indexed: 12/15/2022] Open
Abstract
The precise mechanism by which butyrate-producing bacteria in the gut contribute to resistance to respiratory viral infections remains to be elucidated. Here, we describe a gut-lung axis mechanism and report that orally administered Clostridium butyricum (CB) enhances influenza virus infection resistance through upregulation of interferon (IFN)-λ in lung epithelial cells. Gut microbiome-induced ω-3 fatty acid 18-hydroxy eicosapentaenoic acid (18-HEPE) promotes IFN-λ production through the G protein-coupled receptor (GPR)120 and IFN regulatory factor (IRF)-1/-7 activations. CB promotes 18-HEPE production in the gut and enhances ω-3 fatty acid sensitivity in the lungs by promoting GPR120 expression. This study finds a gut-lung axis mechanism and provides insights into the treatments and prophylaxis for viral respiratory infections.
Collapse
Affiliation(s)
- Mao Hagihara
- Department of Molecular Epidemiology and Biomedical Sciences, Aichi Medical University, Nagakute 480-1195, Japan; Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan
| | - Makoto Yamashita
- Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan
| | - Tadashi Ariyoshi
- Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan; R&D Division, Miyarisan Pharmaceutical Co., Ltd., Saitama 331-0804, Japan
| | - Shuhei Eguchi
- R&D Division, Miyarisan Pharmaceutical Co., Ltd., Saitama 331-0804, Japan
| | - Ayaka Minemura
- R&D Division, Miyarisan Pharmaceutical Co., Ltd., Saitama 331-0804, Japan
| | - Daiki Miura
- R&D Division, Miyarisan Pharmaceutical Co., Ltd., Saitama 331-0804, Japan
| | - Seiya Higashi
- R&D Division, Miyarisan Pharmaceutical Co., Ltd., Saitama 331-0804, Japan
| | - Kentaro Oka
- Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan; R&D Division, Miyarisan Pharmaceutical Co., Ltd., Saitama 331-0804, Japan
| | - Tsunemasa Nonogaki
- Department of Pharmacy, College of Pharmacy Kinjo Gakuin University, Nagoya 463-8521, Japan
| | - Takeshi Mori
- Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan
| | - Kenta Iwasaki
- Departments of Kidney Disease and Transplant Immunology, Aichi Medical University, Nagakute 480-1195, Japan
| | - Jun Hirai
- Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan
| | - Yuichi Shibata
- Department of Molecular Epidemiology and Biomedical Sciences, Aichi Medical University, Nagakute 480-1195, Japan
| | - Takumi Umemura
- Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan
| | - Hideo Kato
- Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan; Department of Pharmacy, Mie University Hospital, Tsu, Mie, Japan
| | - Nobuhiro Asai
- Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan
| | - Yuka Yamagishi
- Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan
| | - Akinobu Ota
- Departments of Biochemistry, Aichi Medical University, Nagakute 480-1195, Japan
| | - Motomichi Takahashi
- Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan; R&D Division, Miyarisan Pharmaceutical Co., Ltd., Saitama 331-0804, Japan
| | - Hiroshige Mikamo
- Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Japan.
| |
Collapse
|
2
|
Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors. Eur J Med Chem 2021; 213:113161. [PMID: 33540229 DOI: 10.1016/j.ejmech.2021.113161] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Revised: 12/13/2020] [Accepted: 01/03/2021] [Indexed: 01/09/2023]
Abstract
A series of 4-thiazolinone derivatives (D1-D58) were designed and synthesized. All of the derivatives were evaluated in vitro for neuraminidase (NA) inhibitory activities against influenza virus A (H1N1), and the inhibitory activities of the five most potent compounds were further evaluated on NA from two different influenza viral subtypes (H3N2 and B), and then their in vitro anti-viral activities were evaluated using the cytopathic effect (CPE) reduction assay. The results showed that the majority of the target compounds exhibited moderate to good NA inhibitory activity. Compound D18 presented the most potent inhibitory activity with IC50 values of 13.06 μM against influenza H1N1 subtype. Among the selected compounds, D18 and D41 turned out to be the most potent inhibitors against influenza virus H3N2 subtype (IC50 = 15.00 μM and IC50 = 14.97 μM, respectively). D25 was the most potent compound against influenza B subtype (IC50 = 16.09 μM). In addition, D41 showed low toxicity and greater potency than reference compounds Oseltamivir and Amantadine against N1-H275Y variant in cellular assays. The structure-activity relationship (SAR) analysis showed that introducing 4-CO2H, 4-OH, 3-OCH3-4-OH substituted benzyl methylene can greatly improve the activity of 4-thiazolinones. Further SAR analysis indicated that 4-thiazolinone and ferulic acid fragments are necessary fragments of target compounds for inhibiting NA. Molecular docking was performed to study the interaction between compound D41 and the active site of NA. This study may providing important information for new drug development for anti-influenza virus including mutant influenza virus.
Collapse
|
3
|
Chen KK, Minakuchi M, Wuputra K, Ku CC, Pan JB, Kuo KK, Lin YC, Saito S, Lin CS, Yokoyama KK. Redox control in the pathophysiology of influenza virus infection. BMC Microbiol 2020; 20:214. [PMID: 32689931 PMCID: PMC7370268 DOI: 10.1186/s12866-020-01890-9] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Accepted: 07/01/2020] [Indexed: 01/07/2023] Open
Abstract
Triggered in response to external and internal ligands in cells and animals, redox homeostasis is transmitted via signal molecules involved in defense redox mechanisms through networks of cell proliferation, differentiation, intracellular detoxification, bacterial infection, and immune reactions. Cellular oxidation is not necessarily harmful per se, but its effects depend on the balance between the peroxidation and antioxidation cascades, which can vary according to the stimulus and serve to maintain oxygen homeostasis. The reactive oxygen species (ROS) that are generated during influenza virus (IV) infection have critical effects on both the virus and host cells. In this review, we outline the link between viral infection and redox control using IV infection as an example. We discuss the current state of knowledge on the molecular relationship between cellular oxidation mediated by ROS accumulation and the diversity of IV infection. We also summarize the potential anti-IV agents available currently that act by targeting redox biology/pathophysiology.
Collapse
Affiliation(s)
- Ker-Kong Chen
- grid.412019.f0000 0000 9476 5696School of Dentistry, Kaohsiung Medical University, Kaohsiung, 807 Taiwan ,Department of Densitory, Kaohisung University Hospital, Kaohisung, 807 Taiwan
| | - Moeko Minakuchi
- grid.5290.e0000 0004 1936 9975Waseda Research Institute for Science and Engineering, Waseca University, Shinjuku, Tokyo, 162-8480 Japan
| | - Kenly Wuputra
- grid.412019.f0000 0000 9476 5696Graduate Institute of Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd., San-Ming District, Kaohsiung, 80807 Taiwan ,grid.412019.f0000 0000 9476 5696Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, 807 Taiwan
| | - Chia-Chen Ku
- grid.412019.f0000 0000 9476 5696Graduate Institute of Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd., San-Ming District, Kaohsiung, 80807 Taiwan ,grid.412019.f0000 0000 9476 5696Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, 807 Taiwan
| | - Jia-Bin Pan
- grid.412019.f0000 0000 9476 5696Graduate Institute of Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd., San-Ming District, Kaohsiung, 80807 Taiwan ,grid.412019.f0000 0000 9476 5696Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, 807 Taiwan
| | - Kung-Kai Kuo
- grid.412027.20000 0004 0620 9374Department Surgery, Kaohsiung Medical University Hospital, Kaohsiung, 807 Taiwan
| | - Ying-Chu Lin
- grid.412019.f0000 0000 9476 5696School of Dentistry, Kaohsiung Medical University, Kaohsiung, 807 Taiwan
| | - Shigeo Saito
- grid.5290.e0000 0004 1936 9975Waseda Research Institute for Science and Engineering, Waseca University, Shinjuku, Tokyo, 162-8480 Japan ,Saito Laboratory of Cell Technology Institute, Yalta, Tochigi, 329-1471 Japan
| | - Chang-Shen Lin
- grid.412019.f0000 0000 9476 5696Graduate Institute of Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd., San-Ming District, Kaohsiung, 80807 Taiwan ,grid.412036.20000 0004 0531 9758Department of Biological Sciences, National Sun Yat-sen University, Kaohsiung, 80424 Taiwan
| | - Kazunari K. Yokoyama
- grid.5290.e0000 0004 1936 9975Waseda Research Institute for Science and Engineering, Waseca University, Shinjuku, Tokyo, 162-8480 Japan ,grid.412019.f0000 0000 9476 5696Graduate Institute of Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd., San-Ming District, Kaohsiung, 80807 Taiwan ,grid.412019.f0000 0000 9476 5696Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, 807 Taiwan ,grid.412027.20000 0004 0620 9374Cell Therapy and Research Center, Kaohsiung Medical University Hospital, Kaohsiung, 807 Taiwan
| |
Collapse
|